Skip to main content
lexblog.com/lib/N7KKK5JCviewrecordjson
LEX-WK-N7KKK5JCcrawled 2021-11-09 11:33Z

Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents

Benjamin R. Holt · Biosimilars Law Bulletin · Published December 5, 2017

Work details

firm or organization
Rothwell Figg
published
2017-12-05

Citation

Benjamin R. Holt, Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents, Biosimilars Law Bulletin (December 5, 2017) [The Library at LexBlog, LEX-WK-N7KKK5JC, lexpid.org/N7KKK5JC]